
SI-BONE Inc (SIBN) Stock Forecast & Price Target
SI-BONE Inc (SIBN) Analyst Ratings
Bulls say
SI-BONE Inc demonstrated strong financial performance in 4Q24, reporting total revenue of $49 million, which reflects a significant 26% year-over-year growth and aligns closely with previously announced figures. The company expanded its direct sales force, increasing the number of U.S. sales territories to 87, and saw a 23% year-over-year rise in active surgeons, reaching approximately 1,400, indicating a robust and expanding market presence. Furthermore, SI-BONE's gross margin improved to 79.1%, exceeding both consensus expectations and the company's own fiscal guidance, supported by higher sales rep productivity and increasing procedure volumes per physician.
Bears say
The analysis reveals a negative outlook for SI-BONE, primarily due to anticipated lower-than-expected revenue growth in the United States and ongoing weaknesses in international markets, compounded by pricing challenges. The company faces multiple risks, including increased competition, patent expirations, and potential reimbursement challenges, which could negatively affect sales and profitability. Additionally, SI-BONE has a history of significant losses, with expectations that this trend will continue, leading to a need for additional capital amidst operational challenges.
This aggregate rating is based on analysts' research of SI-BONE Inc and is not a guaranteed prediction by Public.com or investment advice.
SI-BONE Inc (SIBN) Analyst Forecast & Price Prediction
Start investing in SI-BONE Inc (SIBN)
Order type
Buy in
Order amount
Est. shares
0 shares